{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"64"}],"units":"Participants"}],"description":"RP2D, the maximum tolerated dose (MTD) of TAK-186 was determined.","groups":[{"description":"Participants received sequential doses of TAK-186 as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death.","id":"OG000","title":"Dose Escalation Phase"}],"paramType":"NUMBER","populationDescription":"Safety population included all participants who received at least 1 dose of TAK-186.","reportingStatus":"POSTED","timeFrame":"Up to 19 months","title":"Dose Escalation Phase: Recommended Phase 2 Dose (RP2D) of TAK-186","type":"SECONDARY","unitOfMeasure":"mcg per kg"}